Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition
eLife · 2024
DOI: 10.7554/elife.90683 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Gregory Caleb Howard und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, United States. Hauptthemen laut MEDLINE: Intracellular Signaling Peptides and Proteins, Myeloid-Lymphoid Leukemia Protein, Nuclear Proteins, Ribosomes. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIH HHS.
Abstract (Originalsprache)
The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, United States.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, United States.
- Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, United States.
- Mass Spectrometry Research Center, Vanderbilt University School of Medicine, Nashville, United States.
- Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, United States.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, United States.
ORCID-Profile: Gregory Caleb Howard, Frank M Mason, William P Tansey
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIH HHS
- NEI NIH HHS
- NCRR NIH HHS
- CCR NIH HHS
- National Institutes of Health
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
Zitieren
APA
Howard, G. C., Wang, J., Rose, K. L., Jones, C., Patel, P., Tsui, T., Florian, A. C., Vlach, L., Lorey, S. L., Grieb, B. C., Smith, B. N., Slota, M. J., Reynolds, E. M., Goswami, S., Savona, M. R., Mason, F. M., Lee, T., Fesik, S., Liu, Q., & Tansey, W. P. (2024). Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. eLife. https://doi.org/10.7554/elife.90683
Vancouver
Howard GC, Wang J, Rose KL, Jones C, Patel P, Tsui T, et al. Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. eLife. 2024. doi:10.7554/elife.90683
BibTeX
@article{Howard2024,
author = {Howard, Gregory Caleb and Wang, Jing and Rose, Kristie L and Jones, Camden and Patel, Purvi and Tsui, Tina and Florian, Andrea C and Vlach, Logan and Lorey, Shelly L and Grieb, Brian C and Smith, Brianna N and Slota, Macey J and Reynolds, Elizabeth M and Goswami, Soumita and Savona, Michael R and Mason, Frank M and Lee, Taekyu and Fesik, Stephen and Liu, Qi and Tansey, William P},
title = {Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.90683}
}
EUVIMED